• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Protagonist Therapeutics Set to Join S&P SmallCap 600

    6/27/24 5:44:00 PM ET
    $PTGX
    $SPGI
    $WIRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $PTGX alert in real time by email

    NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    July 3, 2024

    S&P SmallCap 600

    Addition

    Protagonist Therapeutics

    PTGX

    Health Care



    S&P SmallCap 600

    Deletion

    Encore Wire

    WIRE

    Industrials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/protagonist-therapeutics-set-to-join-sp-smallcap-600-302185154.html

    SOURCE S&P Dow Jones Indices

    Get the next $PTGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTGX
    $SPGI
    $WIRE

    CompanyDatePrice TargetRatingAnalyst
    Protagonist Therapeutics Inc.
    $PTGX
    6/17/2025$72.00Buy
    Citigroup
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    S&P Global Inc.
    $SPGI
    12/20/2024$600.00Buy
    Citigroup
    Protagonist Therapeutics Inc.
    $PTGX
    12/6/2024$47.00Neutral
    Goldman
    Protagonist Therapeutics Inc.
    $PTGX
    12/6/2024$62.00Outperform
    BMO Capital Markets
    Protagonist Therapeutics Inc.
    $PTGX
    11/5/2024$58.00Outperform
    Wedbush
    S&P Global Inc.
    $SPGI
    10/2/2024$599.00Outperform
    Evercore ISI
    More analyst ratings